A Phase I Trial of a Live, Genetically Modified Salmonella Typhimurium (VNP20009) for the Treatment of Cancer by Intravenous Administration
Phase of Trial: Phase I
Latest Information Update: 15 Jul 2013
At a glance
- Drugs VNP 20009 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 02 Jan 2008 Status changed from in progress to completed.
- 20 Sep 2005 New trial record.